Switch theme
Sign up to access all valuation multiples
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
2016
105
LTM Revenue $8.8M
Last FY EBITDA -$55.4M
-$43.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Barinthus Biotherapeutics has a last 12-month revenue (LTM) of $8.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Barinthus Biotherapeutics achieved revenue of $15.0M and an EBITDA of -$55.4M.
Barinthus Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Barinthus Biotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | XXX | $15.0M | XXX | XXX | XXX |
| Gross Profit | $8.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$55.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -370% | XXX | XXX | XXX |
| EBIT | -$66.5M | XXX | -$51.8M | XXX | XXX | XXX |
| EBIT Margin | -757% | XXX | -346% | XXX | XXX | XXX |
| Net Profit | -$61.1M | XXX | -$61.1M | XXX | XXX | XXX |
| Net Margin | -695% | XXX | -408% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Barinthus Biotherapeutics's stock price is $1.
Barinthus Biotherapeutics has current market cap of $43.6M, and EV of -$43.6M.
See Barinthus Biotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$43.6M | $43.6M | XXX | XXX | XXX | XXX | $-1.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Barinthus Biotherapeutics has market cap of $43.6M and EV of -$43.6M.
Barinthus Biotherapeutics's trades at -2.9x EV/Revenue multiple, and 0.8x EV/EBITDA.
Equity research analysts estimate Barinthus Biotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Barinthus Biotherapeutics has a P/E ratio of -0.7x.
See valuation multiples for Barinthus Biotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43.6M | XXX | $43.6M | XXX | XXX | XXX |
| EV (current) | -$43.6M | XXX | -$43.6M | XXX | XXX | XXX |
| EV/Revenue | -5.0x | XXX | -2.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBIT | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/Gross Profit | -5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBarinthus Biotherapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Barinthus Biotherapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Barinthus Biotherapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Barinthus Biotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -370% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 256% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 446% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Barinthus Biotherapeutics acquired XXX companies to date.
Last acquisition by Barinthus Biotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Barinthus Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Barinthus Biotherapeutics founded? | Barinthus Biotherapeutics was founded in 2016. |
| Where is Barinthus Biotherapeutics headquartered? | Barinthus Biotherapeutics is headquartered in United States of America. |
| How many employees does Barinthus Biotherapeutics have? | As of today, Barinthus Biotherapeutics has 105 employees. |
| Who is the CEO of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's CEO is Mr. William J. Enright. |
| Is Barinthus Biotherapeutics publicy listed? | Yes, Barinthus Biotherapeutics is a public company listed on NAS. |
| What is the stock symbol of Barinthus Biotherapeutics? | Barinthus Biotherapeutics trades under BRNS ticker. |
| When did Barinthus Biotherapeutics go public? | Barinthus Biotherapeutics went public in 2021. |
| Who are competitors of Barinthus Biotherapeutics? | Similar companies to Barinthus Biotherapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's current market cap is $43.6M |
| What is the current revenue of Barinthus Biotherapeutics? | Barinthus Biotherapeutics's last 12 months revenue is $8.8M. |
| What is the current EV/Revenue multiple of Barinthus Biotherapeutics? | Current revenue multiple of Barinthus Biotherapeutics is -5.0x. |
| Is Barinthus Biotherapeutics profitable? | Yes, Barinthus Biotherapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
